Christian Fegeler

Christian Fegeler

Auto-generated profile, based on publicly available information

Christian Fegeler

MOLIT Institute, Heilbronn, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
SSStefan Sigle
Stefan Sigle
PBPilar Barriga
Pilar Barriga
FFFrancisco Javier Correa Fernández
Francisco Javier Correa Fernández
CJChristian Juhra
Christian Juhra
SHSteffen Hartel
Steffen Hartel
CFChristian Fegeler
Christian Fegeler
Background: Medication is the most common intervention in health care, and the number of online consumer information systems within the pharmaceutical sector is increasing. However, online consumer information systems can be a barrier for users, imposing information asymmetries between stakeholders. Objective: The objective of this study was to quantify and compare the usability of an online consumer medication information system (OCMIS) against a reference implementation based on an interoperable information model for patients, physicians, and pharmacists. Methods: Quantitative and qualitative data were acquired from patients, physicians, and pharmacists in this online usability study. We administered 3 use cases and a post hoc questionnaire per user. Quantitative usability data including effectiveness (task success), efficiency (task time), and user satisfaction (system usability scale [SUS]) was complemented by qualitative and demographic data. Users evaluated 6 existing systems and 1 reference implementation of an OCMIS. Results: A total of 137 patients, 81 physicians, and 68 pharmacists participated in this study. Task success varied from 84% to 92% in patients, 66% to 100% in physicians, and 50% to 91% in pharmacists. Task completion time decreased over the course of the study for all but 2 OCMIS within the patient group. Due to an assumed nonnormal distribution of SUS scores, within-group comparison was done using the Kruskal-Wallis test. Patients showed differences in SUS scores (P=.02) and task time (P=.03), while physicians did not have significant differences in SUS scores (P=.83) and task time (P=.72). For pharmacists, a significant difference in SUS scores (P<.001) and task time (P=.007) was detected. Conclusions: The vendor-neutral reference implementation based on an interoperable information model was proven to be a promising approach that was not inferior to existing solutions for patients and physicians. For pharmacists, it exceeded user satisfaction scores compared to other OCMIS. This data-driven approach based on an interoperable information model enables the development of more user-tailored features to increase usability. This fosters data democratization and empowers stakeholders within the pharmaceutical sector.

26 September 2023 in JMIR Cancer
Verified
Journal Article
Open access
CBChantal N L Beutter
Chantal N L Beutter
KZKatharina Zeller
Katharina Zeller
UMUwe M Martens
Uwe M Martens
BPBettina Pfleiderer
Bettina Pfleiderer
CFChristian Fegeler
Christian Fegeler
Background: The treatment for cancer can have a negative impact not only on physical well-being but also on mental health and the quality of life (QoL). Health apps enable the monitoring of different parameters, but to date, there are only few that support patients with cancer and none that focuses on the assessment of QoL. Furthermore, patients as stakeholders are often only integrated at the late stage of the development process, if at all. Objective: The aim of this research was to develop and evaluate a smartphone app (Lion-App) to enable patients with cancer to autonomously measure the QoL with an iterative, user-centered approach. Methods: Patients with cancer were involved in a 3-stage process from conceptualization to the point when the app was available on the tester’s private device. First, focus groups with members (N=21) of cancer support groups were conducted to understand their expectations and needs. Thereafter, individual tests were performed. After developing a prototype that incorporated findings from the focus groups, a second test cycle was conducted, followed by a beta test lasting 2 months. In our app, the QoL can be assessed via a patient diary and an integrated questionnaire. Through all stages, usability was evaluated using the modular extended version of the User Experience Questionnaire (UEQ+), including the calculation of a key performance indicator (KPI). If possible, the impact of sex on the results was evaluated. As part of the beta test, usage rates as well as age-dependent differences were also assessed. Results: A total of 21 participants took part in the initial 3 focus groups. In the subsequent usability testing (N=18), 17 (94%) participants rated their impression through the UEQ+, with a mean KPI of 2.12 (SD 0.64, range: –3 to 3). In the second usability test (N=14), the mean KPI increased to 2.28 (SD=0.49). In the beta test, the usage rate of 19 participants was evaluated, of whom 14 (74%) also answered the UEQ+ (mean KPI 1.78, SD 0.84). An influence of age on the number of questionnaire responses in Lion-App was observed, with a decrease in responses with increasing age (P=.02). Sex-dependent analyses were only possible for the first usability test and the beta test. The main adjustments based on user feedback were a restructuring of the diary as well as integration of a shorter questionnaire to assess the QoL. Conclusions: The iterative, user-centered approach for development and usability testing resulted in positive evaluations of Lion-App. Our app was rated as suitable for everyday use to monitor the QoL of patients with cancer. Initial results indicated that the sex and age of participants seem to play only a minor role.

18 May 2023
Verified
Book Chapter
Open access
PDF file
CZChristoph Zilske
Christoph Zilske
MKMaximilian Kurscheidt
Maximilian Kurscheidt
SSSimon T. Schweizer
Simon T. Schweizer
HHHauke Hund
Hauke Hund
SMSimon Mödinger
Simon Mödinger
CFChristian Fegeler
Christian Fegeler
In biomedical research, business processes, such as data-sharing or feasibility queries, span across several healthcare organizations. Due to the growing number of data-sharing projects and connected organizations, the management of distributed processes gets more complex over time. This leads to an increased need for administrating, orchestrating, and monitoring all distributed processes of a single organization. A proof of concept for a decentralized and use case agnostic monitoring dashboard was developed for the Data Sharing Framework, which most German university hospitals have deployed. The implemented dashboard can handle current, changing, and upcoming processes using only information for cross-organizational communication. This differentiates our approach from other existing use case specific content visualizations. The presented dashboard is a promising solution to provide administrators with an overview of the status of their distributed process instances. Therefore, this concept will be further developed in upcoming releases.

22 August 2024
Verified
Book Chapter
Open access
PDF file
VVValeriya Vishnevskaya
Valeriya Vishnevskaya
SSStefan Sigle
Stefan Sigle
CFChristian Fegeler
Christian Fegeler
Personalized medicine enables precise tumor treatment for a patient’s molecular genetic profile. To devise optimal targeted treatment plans for patients in a molecular tumor board, physicians must consider alterations on gene- and proteins levels but also cancer cell phenotypes. Machine learning can uncover buried patterns, extract pivotal information, and unveil corresponding insights from available data. Publicly available datasets provide the amounts of data necessary. This work outlines the efficacy of various machine learning algorithms which could eventually serve as clinical decision support in a precision oncology setting. Leveraging algorithms including Random Forest, Decision tree, XGBoost, Logistic regression, Gaussian Naive Bayes, k nearest neighbor, and AdaBoost, we conducted two experiments for the breast invasive carcinoma dataset. Incorporated data includes patient-, molecular- and treatment data. The aim of the investigation was to predict medication treatment or type of treatment based on genetic profile. After preprocessing and application of ML algorithms, the first results were promising. Multiple factors challenge application in clinical care settings without carefully considering the limitations.

22 August 2024
Verified
Book Chapter
Open access
PDF file
CBChantal N.L. Beutter
Chantal N.L. Beutter
SBStephanie Berger
Stephanie Berger
UMUwe M. Martens
Uwe M. Martens
CFChristian Fegeler
Christian Fegeler
Advanced cancer treatments increase survival rates and with that the importance of Quality of Life (QoL). QoL is well studied in trials, but the transition to standard care is little. For this reason, we identified the challenges for a regular integration to conceptualize an applicable solution together with patients and health professionals (HP). We conducted two meetings based on the design thinking method. Two Physicians, one employee of cancer counseling centers, one psycho-oncologists, and five patients were included. Based on the discussions a system was conceptualized to solve current thresholds. All participants had experience with the documentation of QoL, but none had shared it digitally from home. Therefore, the main threshold was the lack of system for data transition between agents, followed by lack of time for HP and acceptance of QoL for patients. HP were mainly interested in data on the trend of QoL whereas patients preferred information on their activity, energy level and social contacts. The conceptualized solution is based on a health app on the patients’ side with a browser-based implementation for HP. Within the system, automatized data interpretation, alarm systems, support information, standardized input fields as an orientation for documentation with expandable options for specific restrictions as well as interinstitutional networking for HP to better refer patients to others was wished for. This article describes the concept of such a system developed with HP and patients. Implementation and transfer to clinical care has yet to be done.

12 December 2022 in JMIR Preprints
Verified
Preprint
Open access
CBChantal N L Beutter
Chantal N L Beutter
KZKatharina Zeller
Katharina Zeller
UMUwe M Martens
Uwe M Martens
BPBettina Pfleiderer
Bettina Pfleiderer
CFChristian Fegeler
Christian Fegeler
BACKGROUND The treatment for cancer can have a negative impact not only on physical well-being but also on mental health and the quality of life (QoL). Health apps enable the monitoring of different parameters, but to date, there are only few that support patients with cancer and none that focuses on the assessment of QoL. Furthermore, patients as stakeholders are often only integrated at the late stage of the development process, if at all. OBJECTIVE The aim of this research was to develop and evaluate a smartphone app (Lion-App) to enable patients with cancer to autonomously measure the QoL with an iterative, user-centered approach. METHODS Patients with cancer were involved in a 3-stage process from conceptualization to the point when the app was available on the tester’s private device. First, focus groups with members (N=21) of cancer support groups were conducted to understand their expectations and needs. Thereafter, individual tests were performed. After developing a prototype that incorporated findings from the focus groups, a second test cycle was conducted, followed by a beta test lasting 2 months. In our app, the QoL can be assessed via a patient diary and an integrated questionnaire. Through all stages, usability was evaluated using the modular extended version of the User Experience Questionnaire (UEQ+), including the calculation of a key performance indicator (KPI). If possible, the impact of sex on the results was evaluated. As part of the beta test, usage rates as well as age-dependent differences were also assessed. RESULTS A total of 21 participants took part in the initial 3 focus groups. In the subsequent usability testing (N=18), 17 (94%) participants rated their impression through the UEQ+, with a mean KPI of 2.12 (SD 0.64, range: –3 to 3). In the second usability test (N=14), the mean KPI increased to 2.28 (SD=0.49). In the beta test, the usage rate of 19 participants was evaluated, of whom 14 (74%) also answered the UEQ+ (mean KPI 1.78, SD 0.84). An influence of age on the number of questionnaire responses in Lion-App was observed, with a decrease in responses with increasing age (P=.02). Sex-dependent analyses were only possible for the first usability test and the beta test. The main adjustments based on user feedback were a restructuring of the diary as well as integration of a shorter questionnaire to assess the QoL. CONCLUSIONS The iterative, user-centered approach for development and usability testing resulted in positive evaluations of Lion-App. Our app was rated as suitable for everyday use to monitor the QoL of patients with cancer. Initial results indicated that the sex and age of participants seem to play only a minor role.